CTLA4 and cutaneous melanoma: The importance of NK cells in this setting is indirectly confirmed by the fact that ipilimumab (anti-CTLA-4 monoclonal antibody) treatment depletes regulatory T cells in cancer patients, and is reported to improve NK cells’ functions in advanced cutaneous melanoma patients [34].